TY  - JOUR

T1  - Safety, tolerability, and initial efficacy of AZD6140, the first reversivle oral adenosine diphosphate receptor antagonist, compared with clopidigrel, in patients with non-ST-segment elevation acute coronary syndrome - Primary results of the DISPERSE-2 trial

JO  - J AM COLL CARDIOL

PY  - 2007/11/06

AU  - Cannon CP

AU  - Husted S

AU  - Harrington RA

AU  - Scirica BM

AU  - Emanuelsson H

AU  - Storey RF

AU  - DISPERSE-2 Invest

ED  - 

DO  - DOI: 10.1016/j.jacc.2007.07.053

VL  - 50

IS  - 19

SP  - 1844

EP  - 1851

Y2  - 2024/12/22

ER  -